Skip to main content

Table 2 Association between RRM1 , RRM2B, and 2R status and PAM50 intrinsic subtype

From: Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine

Characteristics

RRM1

RRM2B

2R

Normal

Aberrant

 

Normal

Aberrant

 

Normal

Aberrant

 

No.

(%)

No.

(%)

Pa

No.

(%)

No.

(%)

Pa

No.

(%)

No.

(%)

Pa

No. of patients

211

 

40

  

217

 

34

  

184

 

67

  

PAM50 b

    

0.38

    

0.0004

    

0.009

Luminal A

63

(29.9)

8

(20.0)

 

70

(32.3)

1

(2.9)

 

62

(33.7)

9

(13.4)

 

Luminal B

74

(35.1)

15

(37.5)

 

75

(34.6)

14

(41.2)

 

62

(33.7)

27

(40.3)

 

Basal-like

32

(15.2)

10

(25.0)

 

35

(16.1)

7

(20.6)

 

27

(14.7)

15

(22.4)

 

HER2-enriched

37

(17.5)

7

(17.5)

 

33

(15.2)

11

(32.4)

 

29

(15.8)

15

(22.4)

 

Unknown

5

(0.0)

0

(0.0)

 

4

(1.8)

1

(2.9)

 

4

(2.2)

1

(1.5)

 
  1. Abbreviations: 2R aberration RRM1 and/or RRM2B aberrant, 2R normal RRM1 and RRM2B both normal, HER2 human epidermal growth factor receptor 2, RRM1 ribonucleotide reductase M1 subunit, RRM2B ribonucleotide reductase M2B subunit.
  2. a Fishers exact test, unknown values excluded from tests.
  3. b PAM50: A 50-gene expression classifier that identifies the four major intrinsic subtypes of breast cancer known as the luminal A, luminal B, HER2-enriched and basal-like subtypes [26].